Nepsis Inc. increased its holdings in shares of Johnson & Johnson (NYSE:JNJ – Get Rating) by 28.0% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 86,542 shares of the company’s stock after buying an additional 18,917 shares during the quarter. Johnson & Johnson comprises approximately 5.1% of Nepsis Inc.’s portfolio, making the stock its 4th biggest holding. Nepsis Inc.’s holdings in Johnson & Johnson were worth $14,138,000 as of its most recent SEC filing.
Other large investors have also recently added to or reduced their stakes in the company. Morton Brown Family Wealth LLC raised its stake in Johnson & Johnson by 78.0% during the 2nd quarter. Morton Brown Family Wealth LLC now owns 178 shares of the company’s stock valued at $32,000 after acquiring an additional 78 shares in the last quarter. Goodman Advisory Group LLC acquired a new stake in shares of Johnson & Johnson in the second quarter worth about $39,000. Cardinal Capital Management Inc. lifted its position in shares of Johnson & Johnson by 333.3% during the 2nd quarter. Cardinal Capital Management Inc. now owns 260 shares of the company’s stock worth $46,000 after purchasing an additional 200 shares during the last quarter. First Bank & Trust increased its stake in Johnson & Johnson by 69.6% during the second quarter. First Bank & Trust now owns 380 shares of the company’s stock valued at $67,000 after acquiring an additional 156 shares during the period. Finally, Heritage Wealth Management LLC bought a new stake in shares of Johnson & Johnson in the 2nd quarter valued at approximately $84,000. 67.94% of the stock is currently owned by hedge funds and other institutional investors.
Wall Street Analysts Forecast Growth
JNJ has been the topic of a number of analyst reports. Atlantic Securities cut their price target on Johnson & Johnson from $165.00 to $160.00 and set a “neutral” rating on the stock in a research note on Wednesday, October 19th. StockNews.com initiated coverage on shares of Johnson & Johnson in a research report on Wednesday, October 12th. They set a “strong-buy” rating for the company. SVB Leerink dropped their price target on shares of Johnson & Johnson from $194.00 to $186.00 and set an “outperform” rating for the company in a research report on Friday. Sanford C. Bernstein dropped their price objective on shares of Johnson & Johnson from $194.00 to $190.00 in a research note on Wednesday, October 19th. Finally, Bank of America decreased their price target on shares of Johnson & Johnson from $185.00 to $178.00 and set a “neutral” rating for the company in a research report on Friday, October 14th. Seven investment analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Johnson & Johnson presently has an average rating of “Moderate Buy” and an average price target of $181.75.
Johnson & Johnson Stock Performance
Johnson & Johnson Dividend Announcement
The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 7th. Shareholders of record on Tuesday, February 21st will be paid a dividend of $1.13 per share. The ex-dividend date of this dividend is Friday, February 17th. This represents a $4.52 annualized dividend and a yield of 2.68%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 62.95%.
Insider Transactions at Johnson & Johnson
In other news, CFO Joseph J. Wolk sold 14,781 shares of the business’s stock in a transaction dated Tuesday, December 13th. The stock was sold at an average price of $179.60, for a total transaction of $2,654,667.60. Following the completion of the transaction, the chief financial officer now directly owns 35,812 shares of the company’s stock, valued at $6,431,835.20. The sale was disclosed in a filing with the SEC, which is accessible through this link. In other news, CFO Joseph J. Wolk sold 14,781 shares of the company’s stock in a transaction that occurred on Tuesday, December 13th. The stock was sold at an average price of $179.60, for a total transaction of $2,654,667.60. Following the completion of the sale, the chief financial officer now owns 35,812 shares in the company, valued at $6,431,835.20. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider William Hait sold 15,000 shares of the company’s stock in a transaction on Monday, October 24th. The shares were sold at an average price of $171.55, for a total value of $2,573,250.00. Following the completion of the sale, the insider now directly owns 80,236 shares in the company, valued at approximately $13,764,485.80. The disclosure for this sale can be found here. Insiders have sold a total of 277,886 shares of company stock worth $48,550,549 in the last quarter. Company insiders own 0.35% of the company’s stock.
Johnson & Johnson Company Profile
Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women’s health, and wound care markets.
- Get a free copy of the StockNews.com research report on Johnson & Johnson (JNJ)
- MarketBeat Week in Review – 1/16 – 1/20
- Does Old Dominion Show That Trucking Is Hitting The Brakes?
- Nordstrom Puts Fear Of Markdowns Into Retail Sector
- Exxon Mobil Stock: Within Striking Distance Of Buy Point
- High-Dividend-Yielding BHP Sees China Driving ’23 Growth
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.